Affiliation:
1. Pfizer Central Research, Pfizer Ltd., Sandwich, Kent, United Kingdom
Abstract
UK-18,892, a new semisynthetic aminoglycoside, was active against bacteria possessing aminoglycoside-inactivating enzymes, with the exception of some known to possess AAC(6′) or AAD(4′) enzymes. This activity has been rationalized by using cell-free extracts of bacteria containing known inactivating enzymes, where it was shown that UK-18,892 was not a substrate for the APH(3′), AAD(2″), AAC(3), and AAC(2′) enzymes. It was also demonstrated that UK-18,892 protected mice against lethal infections caused by organisms possessing aminoglycoside-inactivating enzymes.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The potential for discovery and development of improved aminoglycosides;The American Journal of Medicine;1986-06
2. Aminoglycoside research 1975-1985: prospects for development of improved agents;Antimicrobial Agents and Chemotherapy;1986-04
3. Enzymatic Modification of Aminoglycoside Antibiotics in Gentamicin-Resistant Gram-Negative Bacteria;Zentralblatt für Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale. A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie;1984-08
4. Effect on the renal function of UK 18892;Journal of Antimicrobial Chemotherapy;1980
5. Chapter 11 Antibiotics;Annual Reports in Medicinal Chemistry;1979